
Data Publications
The New England Journal of Medicine
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
JAMA Oncology
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation
Clinical Cancer Research
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Journal of Clinical Oncology
Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001
Journal of Gastrointestinal Oncology
Burden of illness for patients with cholangiocarcinoma in the U.S.: a retrospective claims analysis
Journal of Medicinal Chemistry
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion
Blood
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Expert Opinion on Investigational Drugs
Ivosidenib: an investigational drug for the treatment of biliary tract cancers
Cancer Cell
MAT2A Inhibition Blocks the Growth of MTAP-deleted Cancer Cells By Reducing PRMT5-dependent mRNA Splicing and Inducing DNA damage
Journal of Clinical Oncology
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination with Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
CNS Oncology
Ivosidenib, an IDH1 Inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: A Case Report from a Phase 1 Study
Journal of Clinical Oncology
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma
Nature
Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages
The Lancet Oncology
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicenter, randomized, double-blind, placebo-controlled, phase 3 study
Blood Advances
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Cancer Chemother Pharmacol
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation
Journal of Clinical Oncology
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
Blood
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
ACS Medicinal Chemistry Letters
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
New England Journal of Medicine
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
ACS Medicinal Chemistry Letters
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
ACS Medicinal Chemistry Letters
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
More from Servier
Research & Development
We invest in the research and development of innovative medicines, all designed with the goal to best address the unmet needs of patients.
Learn MoreClinical Trials
We strive to have consistent and concise transparency throughout all our clinical trials and research and development for the benefit of our patients.
Learn MoreMedicines
Servier Pharmaceuticals' medicines change the lives of the patients we serve. Currently, within the United States, oncology treatment and care are our immediate focus.
Learn More